Literature DB >> 33504661

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa.

Jocelyn Qi-Min Teo1,2, Jie Chong Lim3, Rick Twee-Hee Ong4, Andrea Lay-Hoon Kwa5,6,7, Cheng Yee Tang2, Shannon Jing-Yi Lee1, Si Hui Tan1, James Heng-Chiak Sim8.   

Abstract

This study established the in vitro activity of ceftolozane/tazobactam (C/T) and its genotypic resistance mechanisms by whole-genome sequencing (WGS) in 195 carbapenem-nonsusceptible Pseudomonas aeruginosa (CNSPA) clinical isolates recovered from Singapore between 2009 and 2020. C/T susceptibility rates were low, at 37.9%. Cross-resistance to ceftazidime/avibactam was observed, although susceptibility to the agent was slightly higher, at 41.0%. Whole-genome sequencing revealed that C/T resistance was largely mediated by the presence of horizontally acquired β-lactamases, especially metallo-β-lactamases. These were primarily disseminated in well-recognized high-risk clones belonging to sequence types (ST) 235, 308, and 179. C/T resistance was also observed in several non-carbapenemase-producing isolates, in which resistance was likely mediated by β-lactamases and, to a smaller extent, mutations in AmpC-related genes. There was no obvious mechanism of resistance observed in five isolates. The high C/T resistance highlights the limited utility of the agent as an empirical agent in our setting. Knowledge of local molecular epidemiology is crucial in determining the potential of therapy with novel agents.IMPORTANCE Pseudomonas aeruginosa infection is one of the most difficult health care-associated infections to treat due to the ability of the organism to acquire a multitude of resistance mechanisms and express the multidrug resistance phenotype. Ceftolozane/tazobactam (C/T), a novel β-lactam/β-lactamase inhibitor combination, addresses an unmet medical need in patients with these multidrug-resistant P. aeruginosa infections. Our findings demonstrate geographical variation in C/T susceptibility owing to the distinct local molecular epidemiology. This study adds on to the growing knowledge of C/T resistance, particularly mutational resistance, and will aid in the design of future β-lactams and β-lactamase inhibitors. WGS proved to be a useful tool to understand the P. aeruginosa resistome and its contribution to emerging resistance in novel antimicrobial agents.
Copyright © 2021 Teo et al.

Entities:  

Keywords:  Pseudomonas aeruginosa; ceftolozane/tazobactam; molecular characterization

Year:  2021        PMID: 33504661      PMCID: PMC7885320          DOI: 10.1128/mSphere.01026-20

Source DB:  PubMed          Journal:  mSphere        ISSN: 2379-5042            Impact factor:   4.389


  27 in total

1.  SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing.

Authors:  Anton Bankevich; Sergey Nurk; Dmitry Antipov; Alexey A Gurevich; Mikhail Dvorkin; Alexander S Kulikov; Valery M Lesin; Sergey I Nikolenko; Son Pham; Andrey D Prjibelski; Alexey V Pyshkin; Alexander V Sirotkin; Nikolay Vyahhi; Glenn Tesler; Max A Alekseyev; Pavel A Pevzner
Journal:  J Comput Biol       Date:  2012-04-16       Impact factor: 1.479

2.  ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa.

Authors:  José-Manuel Ortiz de la Rosa; Patrice Nordmann; Laurent Poirel
Journal:  J Antimicrob Chemother       Date:  2019-07-01       Impact factor: 5.790

3.  ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes.

Authors:  Sushim Kumar Gupta; Babu Roshan Padmanabhan; Seydina M Diene; Rafael Lopez-Rojas; Marie Kempf; Luce Landraud; Jean-Marc Rolain
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

4.  Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.

Authors:  Gabriel Cabot; Sebastian Bruchmann; Xavier Mulet; Laura Zamorano; Bartolomé Moyà; Carlos Juan; Susanne Haussler; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

5.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

Authors:  David M Livermore
Journal:  Clin Infect Dis       Date:  2002-01-25       Impact factor: 9.079

6.  In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.

Authors:  Hasan Cenk Mirza; Elvan Hortaç; Aylin Altay Koçak; M Hamiyet Demirkaya; Buket Yayla; Aylin Üsküdar Güçlü; Ahmet Başustaoğlu
Journal:  J Glob Antimicrob Resist       Date:  2019-09-27       Impact factor: 4.035

7.  Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.

Authors:  Pablo A Fraile-Ribot; Gabriel Cabot; Xavier Mulet; Leonor Periañez; M Luisa Martín-Pena; Carlos Juan; José L Pérez; Antonio Oliver
Journal:  J Antimicrob Chemother       Date:  2018-03-01       Impact factor: 5.790

8.  Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates.

Authors:  Erik Skoglund; Kimberly R Ledesma; Todd M Lasco; Vincent H Tam
Journal:  J Glob Antimicrob Resist       Date:  2017-10-31       Impact factor: 4.035

9.  Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.

Authors:  M Berrazeg; K Jeannot; Véronique Yvette Ntsogo Enguéné; I Broutin; S Loeffert; D Fournier; P Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

Review 10.  Carbapenem Resistance in Gram-Negative Bacteria: The Not-So-Little Problem in the Little Red Dot.

Authors:  Jocelyn Qi Min Teo; Yiying Cai; Tze-Peng Lim; Thuan Tong Tan; Andrea Lay-Hoon Kwa
Journal:  Microorganisms       Date:  2016-02-16
View more
  9 in total

1.  Genomic Surveillance of Clinical Pseudomonas aeruginosa Isolates Reveals an Additive Effect of Carbapenemase Production on Carbapenem Resistance.

Authors:  Luke Diorio-Toth; Sidra Irum; Robert F Potter; Meghan A Wallace; Muhammad Arslan; Tehmina Munir; Saadia Andleeb; Carey-Ann D Burnham; Gautam Dantas
Journal:  Microbiol Spectr       Date:  2022-05-31

2.  Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa.

Authors:  Ayesha Khan; José M Munita; Lina Rivas; Manuel Alcalde-Rico; José R W Martínez; María Victoria Moreno; Pamela Rojas; Aniela Wozniak; Patricia García; Jorge Olivares-Pacheco; William R Miller; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2021-11-15       Impact factor: 5.938

3.  XDR-Pseudomonas aeruginosa Outside the ICU: Is There Still Place for Colistin?

Authors:  Paola Del Giacomo; Francesca Raffaelli; Angela Raffaella Losito; Barbara Fiori; Mario Tumbarello
Journal:  Antibiotics (Basel)       Date:  2022-02-01

4.  Association of blaVIM-2, blaPDC-35, blaOXA-10, blaOXA-488 and blaVEB-9 β-Lactamase Genes with Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam in Multidrug-Resistant Pseudomonas aeruginosa.

Authors:  Mazen A Sid Ahmed; Faisal Ahmad Khan; Hamad Abdel Hadi; Sini Skariah; Ali A Sultan; Abdul Salam; Abdul Latif Al Khal; Bo Söderquist; Emad Bashir Ibrahim; Ali S Omrani; Jana Jass
Journal:  Antibiotics (Basel)       Date:  2022-01-19

5.  Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa.

Authors:  Worapong Nasomsong; Parnrada Nulsopapon; Dhitiwat Changpradub; Supanun Pungcharoenkijkul; Patomroek Hanyanunt; Tassanawan Chatreewattanakul; Wichai Santimaleeworagun
Journal:  Antibiotics (Basel)       Date:  2022-04-13

6.  Comparative In Vitro Activity of Ceftolozane/Tazobactam against Clinical Isolates of Pseudomonas aeruginosa and Enterobacterales from Five Latin American Countries.

Authors:  Juan Carlos García-Betancur; Elsa De La Cadena; María F Mojica; Cristhian Hernández-Gómez; Adriana Correa; Marcela A Radice; Paulo Castañeda-Méndez; Diego A Jaime-Villalon; Ana C Gales; José M Munita; María Virginia Villegas
Journal:  Antibiotics (Basel)       Date:  2022-08-13

7.  Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.

Authors:  María José Contreras-Gómez; José R W Martinez; Lina Rivas; Roberto Riquelme-Neira; Juan A Ugalde; Aniela Wozniak; Patricia García; José M Munita; Jorge Olivares-Pacheco; Manuel Alcalde-Rico
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

8.  Genomic characterization of carbapenem-non-susceptible Pseudomonas aeruginosa in Singapore.

Authors:  Jocelyn Qi-Min Teo; Cheng Yee Tang; Jie Chong Lim; Shannon Jing-Yi Lee; Si Hui Tan; Tse-Hsien Koh; James Heng-Chiak Sim; Thuan-Tong Tan; Andrea Lay-Hoon Kwa; Rick Twee-Hee Ong
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

9.  The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.

Authors:  Christian M Gill; Elif Aktaþ; Wadha Alfouzan; Lori Bourassa; Adrian Brink; Carey-Ann D Burnham; Rafael Canton; Yehuda Carmeli; Marco Falcone; Carlos Kiffer; Anna Marchese; Octavio Martinez; Spyros Pournaras; Michael Satlin; Harald Seifert; Abrar K Thabit; Kenneth S Thomson; Maria Virginia Villegas; David P Nicolau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-07-22       Impact factor: 3.267

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.